Coupled ROS and Ca2+ Sustained Activation in Cancer Cells Induced by Near-Infrared Laser Pulse: Application for Cancer Therapy

Infrared quantum-dot laser diode irradiation (1268 nm) was observed to induce irreversible oxidative stress in cancer cells through direct triplet→singlet oxygen transition designating a novel cancer treatment equally with photodynamic therapy, PDT (Sokolovski, et al. Sci. Rep. 3:3484, 2013). A single laser pulse induction of reactive oxygen species (ROS) was attended with Ca2+ release and coupled ROS and Ca2+ sustained activation occurs far beyond the initial laser pulse exposure. Cancerous cells (HeLa) were observed to be more sensitive to laser-induced ROS generation then normal keratinocytes. The developed model of the laser-induced oxidative stress showed that the main impact on the cell oxidative state makes a cascade of secondary ROS triggered by primary laser-induced singlet oxygen and irreversible depletion of cellular antioxidant system in cancerous cells. We proposed the model of the amplification of laser-induced ROS generation due to the coupled ROS and Ca2+ activation through endoplasmic reticulum (ER) and mitochondria crosstalk.

 

View Full Article: HERE

Go through the Journal: http://www.enlivenarchive.org/bioinformatics-open-access

Contact Us: bioinfo@enlivenarchive.org

Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: an Emerging Chapter in the Field of Clinical Lipidology

The role of low-density lipoprotein cholesterol (LDL-C) in the pathophysiology of atherosclerosis is well recognized, and statin therapy represents the standard of care for LDL-C lowering and reduction of cardiovascular risk. However, many patients fail to achieve LDL-C goals, while others are intolerant to statins due to side effects. Unfortunately, until recently, the efficacy of other non-statin LDL-C-lowering agents was limited, achieving an LDL-C reduction of no more than 20%. Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors represent a new class of LDL-lowering agents, producing large reductions in LDL-C. The present review aims to provide the current clinical and scientific data pertaining to this promising new class of LDL-C-lowering agents.

Full Article: HERE

Go through the Journal: http://www.enlivenarchive.org/clinical-cardiology-and-research/

Contact Us:  clinicalcardiology-research@enlivenarchive.org